WO2014111892A1 - miRNA-124 AS A BIOMARKER - Google Patents
miRNA-124 AS A BIOMARKER Download PDFInfo
- Publication number
- WO2014111892A1 WO2014111892A1 PCT/IB2014/058359 IB2014058359W WO2014111892A1 WO 2014111892 A1 WO2014111892 A1 WO 2014111892A1 IB 2014058359 W IB2014058359 W IB 2014058359W WO 2014111892 A1 WO2014111892 A1 WO 2014111892A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mirna
- group
- mir
- viral infection
- sample
- Prior art date
Links
- ZYUBUXKVZUJXAK-UHFFFAOYSA-N FC(c1ccnc(Nc2ccc(cccc3Cl)c3n2)c1)(F)F Chemical compound FC(c1ccnc(Nc2ccc(cccc3Cl)c3n2)c1)(F)F ZYUBUXKVZUJXAK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- the instant invention relates to the field of biomarkers, in particular in connection with viral infections.
- the invention relates to a novel biomarker useful as a diagnostic marker for viral infections.
- the viral infections more particularly considered are viral infections requiring RNA splicing, and in particular retroviral infections such as HIV and AIDS-related conditions.
- the invention also relates to a follow-up marker for treatments of said infections, and in particular HIV and AIDS-related conditions.
- messenger RNAs are not directly transcribed in their functional form but as pre-messenger RNAs which have to go through many processing events in order to be readable by the cellular translation machinery.
- Splicing is the process which allows to eliminate the unwanted sequences (introns) and to join the meaningful ones (exons).
- the highly coordinated splicing event takes place in a large complex called the Spliceosome.
- the formation of this functional megacomplex is an orchestrated assembly of proteins and RNA that requires identification of exon-intron boundaries. Exons are regularly alternatively spliced, meaning that they are either included or excluded from the final mature mRNA transcript.
- a recent comprehensive sequencing study observed that more than 90% of the genes undergo alternative splicing.
- the production of alternatively spliced mRNAs is regulated by a system of trans-acting proteins that bind to cis-acting sites on the pre-mRNA itself.
- proteins include splicing activators that promote the usage of a particular splice site, and splicing repressors that reduce the usage of a particular site, binding on splicing enhancer sites (intronic splicing enhancers, ISE and exonic splicing enhancers, ESE) and on splicing silencer sites (intronic splicing silencers, ISS and exonic splicing silencers, ISS) respectively.
- Viruses in particular from the retroviral family, are one of the major causes of diseases around the world. Three subfamilies can be distinguished within the retroviral family: the oncoviruses, the lentiviruses and the spumaviruses.
- the oncoviruses are thus termed because they can be associated with cancers and malignant infections.
- leukemogenic viruses such as the avian leukemia virus (ALV), the murine leukemia virus (MULV), also called Moloney virus, the feline leukemia virus (FELV), human leukemia viruses such as HTLV1 and HTLV2, the simian leukemia virus or STLV, the bovine leukemia virus or BLV, the primate type D oncoviruses, the type B oncoviruses which are inducers of mammary tumors, or oncoviruses which cause a rapid cancer (such as the Rous sarcoma virus or RSV).
- the spumaviruses manifest fairly low specificity for a given cell type or a given species, and they are sometimes associated with immunosuppressive phenomena; that is the case, for example, for the simian foamy virus (or SFV).
- Viruses and in particular retroviruses such as HIV, are known to rely upon RNA splicing and splicing regulation in order to spread and disseminate within cells and tissues of an infected individual.
- HIV-1 is a retrovirus that requires RNA splicing to express key viral proteins
- AIDS WO 2010/143169
- the HIV-1 genome expresses a primary transcript of 9 kb that not only serves as a genomic RNA for progeny virus, but which also generates 40 different mRNAs.
- HIV-1 uses four multiple alternative 5' splice sites and eight multiple alternative 3' splice sites to generate spliced mRNA species. These spliced mRNAs can be divided into two classes: multiply spliced (2 kb) and singly spliced (4 kb) RNAs.
- HIV-1 alternative splicing occurs primarily because of the presence of suboptimal splicing sites which decrease the recognition by the cellular splicing machinery of the splice signals. Splicing at the viral splice sites is further regulated by the presence of ESEs, ESSs and ISSs.
- miRNA microRNAs
- UTR UnTranslated Region
- miRNA genes represent about 1-2% of the known eukaryotic genomes. Predictions suggest that each miRNA can target more than 200 transcripts and that a single mRNA can be regulated by multiple miRNAs (LINDOW, DNA Cell Biol, vol. 26(5), p. 339-351, 2007).
- miRNAs are generated from endogenous hairpin-shaped transcripts and act by base pairing with target mRNAs, which leads to mRNA cleavage or translational repression, depending on the degree of base-pairing.
- Two processing events lead to mature miRNA formation: first, the nascent miRNA transcripts (pri-miRNA) are processed into 70 nucleotides precursors (pre-miRNA) which are exported from the nucleus and are cleaved in the cytoplasm to generate short (about 22 nucleotides long) mature miRNAs (LEE, EMBO J., vol. 21, p; 4663-4670, 2002). miRNAs can be located inter- or intragenically.
- the present invention has for purpose to meet these needs.
- the invention concerns a use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.
- the level of expression of miR-124 was decreased relative to non-infected PBMCs.
- quinoline derivatives such as quinoline derivatives of formula (I) or (II), and in particular with the 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, of peripheral blood mononuclear cells (PBMCs) infected with a HIV strain, in particular with the ADA-M R5 HIV, resulted in the removal of the viruses and in a dramatic increase (13-fold relative to control) of miR-124 expression.
- PBMCs peripheral blood mononuclear cells
- a therapeutic treatment of said viral infection can be a treatment with quinoline derivatives.
- the invention concerns a use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker of a viral infection, preferably with a retrovirus, and more preferably with a Human Immunodeficiency Virus (HIV).
- a viral infection preferably with a retrovirus, and more preferably with a Human Immunodeficiency Virus (HIV).
- HIV Human Immunodeficiency Virus
- the invention pertains a use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker for screening a drug candidate or vaccine candidate presumed effective in preventing and/or treating a viral infection, in particular a retroviral infection, and more particularly an HIV infection.
- the invention concerns the use of at least one miRNA, said at least one miRNA being mi RNA-124, as a biomarker, for assessing the biological effect, in particular the pharmacological potential, of a candidate compound, to alter the physiological activity of a cell or a protein.
- miR-124 consists of a relevant biomarker of the potential pharmacological activity of a candidate compound.
- the drug candidate or vaccine candidate presumed effective in preventing and/or treating a viral infection can be a quinoline derivative.
- the drug candidate or vaccine candidate presumed effective in preventing and/or treating a viral infection can be a uinoline derivative of formula (I):
- - n is 1 or 2 and R, independently, represents a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 ) alkyl group; a -NR 1 R 2 group in which Ri and R 2 are independently a hydrogen atom or a (Ci-C 3 )alkyl group; a (C 1 -C 3 ) fluoroalkoxy group; a -NO 2 group; a phenoxy group; and a (C 1 -C 4 ) alkoxy group,
- the drug candidate or vaccine candidate presumed effective in preventing and/or treating a viral infection can also be a uinoline derivative of formula (II):
- R independently, represents a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 ) alkyl group; a -CN group; a hydroxyl group; a -COORi group; a (Ci-C 3 )fluoroalkyl group; a -NO 2 group; a -NR 1 R 2 group with Ri and R 2 being a hydrogen atom or a (Ci-C 3 )alkyl group; and a (C 1 -C 4 ) alkoxy group,
- R' is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 4 ) alkyl group and a (C 1 -C 4 ) alkoxy group,
- R" is a hydrogen atom or a (C 1 -C 4 ) alkyl group
- the term "preventing” intends to mean reducing the likelihood of occurrence of a given event, namely, in the context of the invention, a viral infection.
- the invention concerns a use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker of an activity of a quinoline derivative, or one of its pharmaceutically acceptable salt, on a viral infection, in particular a retroviral infection, and more particularly an HIV infection.
- the invention concerns a use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker of an activity of a quinoline derivative of formula (I):
- R independently, represents a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 ) alkyl group; a -NR 1 R 2 group in which Ri and R 2 are independently a hydrogen atom or a (Ci-C 3 )alkyl group; a (C 1 -C 3 ) fluoroalkoxy group; a -NO 2 group; a phenoxy group; and a (C 1 -C 4 ) alkoxy group,
- R" is a hydrogen atom or a (C 1 -C 4 ) alkyl group
- a viral infection and in particular a retroviral infection, and more particularly an HIV infection.
- R independently, represents a hydrogen atom, a halogen atom or a group chosen among a (Ci-C 3 )alkyl group; a -CN group; a hydroxyl group; a -COORi group; a (Ci-C 3 )fluoroalkyl group; a -NO 2 group; a -NR 1 R 2 group with Ri and R 2 being a hydrogen atom or a (Ci-C 3 )alkyl group; and a (C 1 -C 4 ) alkoxy group,
- R' is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 4 ) alkyl group and a (C 1 -C 4 ) alkoxy group,
- a quinoline derivative of the invention may be 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine or 8-chloro-N-[4-
- the expressions "viral infection” and "infection with a virus” refer to any viral infection, and in particular to any retroviral infection, which may occur into a cell, a tissue, an organ or an individual liable to express a biomarker of the invention.
- a retroviral viral infection may be a lentiviral infection, and more preferably an HIV infection.
- An individual within the invention may be a mammal, and preferably a human liable to express a biomarker of the invention.
- individual and patient are used interchangeably.
- virus refers to any virus, in particular a retrovirus and preferably a lentivirus such as an HIV virus, more preferably HIV-1 or HTV-2.
- a modulated presence or level of expression of said miRNA is indicative of an activity of said quinoline derivative.
- a biological sample suitable for the invention may be selected in a group consisting of a biological tissue sample, a whole blood sample, a swab sample, a plasma sample, a serum sample, a saliva sample, a vaginal fluid sample, a sperm sample, a pharyngeal fluid sample, a bronchial fluid sample, a fecal fluid sample, a cerebrospinal fluid sample, a lacrymal fluid sample and a tissue culture supernatant sample.
- the invention further relates to an isolated biological sample comprising a biomarker, wherein said biological sample is selected in a group comprising, and preferably consisting in a tissue sample, whole blood, swab sample, plasma, serum, saliva, vaginal fluid, sperm, pharyngeal fluid, bronchial fluid, fecal fluid, cerebrospinal fluid, lacrymal fluid and tissue culture supernatant; wherein said biomarker is a miRNA biomarker, and preferably miR-124.
- the invention concerns a method for assessing the biological effect of a candidate compound and in particular for screening a drug candidate or vaccine candidate, presumed effective in preventing and/or treating a viral infection, and in particular a retroviral infection, and more particularly an HIV infection, comprising at least the steps of:
- b- measuring a presence or expression level of said at least one miRNA c- comparing said measured presence or expression level with a measure or expression level of said at least one miRNA in an untreated isolated cell, wherein a modulated presence or level of expression of said miRNA is indicative of a biological effect of a candidate compound and in particular of the efficacy of said drug candidate or vaccine candidate on a viral infection.
- modulation or “modulated presence or level of expression” intend to mean that the presence or level of expression of a biomarker of the invention is either induced or increased, or alternatively is suppressed or decreased.
- miR-124 and notably the expression level of miR-124, consists of a relevant biomarker that is indicative of a physiological change of a protein or a cell, including a metabolic change of a cell, which change materializes a beneficial pharmacological effect.
- the invention also concerns the use of at least one miRNA, said at least one miRNA being miRNA-124, for assessing the biological effect, in particular the pharmacological effect, of a candidate compound.
- determining generally refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assessing may be relative or absolute. The phrase "assessing the presence of can include determining the amount of something present, as well as determining whether it is present or absent.
- uses and methods of the invention are carried out in vitro or ex vivo.
- the invention relates to an isolated nucleic acid probe able to specifically hybridize to miR-124 as a diagnostic agent for measuring a presence or a level expression of miR-124 for diagnosing a viral infection, in particular a retroviral infection, and more particularly an HIV infection, or for assessing an activity of a drug candidate or vaccine candidate presumed effective for preventing and/or treating a viral infection, in particular a retroviral infection, and more particularly an HIV infection.
- probe generally refers to a capture agent that is directed to a specific target miRNA biomarker sequence. Accordingly, each probe of a probe set has a respective target miRNA biomarker.
- a probe/target miRNA duplex is a structure formed by hybridizing a probe to its target miRNA biomarker.
- An isolated nucleic acid probe suitable for the invention may be preferably a nucleic acid probe consisting in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 87.
- the invention provides a useful and reliable biomarker for the follow-up of patients infected with a virus, preferably with a retrovirus, and more preferably with an HIV virus.
- a presence or a level of expression of miR-124 is measured into an isolated biological sample, and then is compared to a control reference value.
- a modulation of the presence or level of expression of miR-124 relative to the control reference value may be indicative of a viral infection.
- a reduced or suppressed presence, or a decreased level of expression, of said miRNA relative to a control reference value may be indicative of a viral infection.
- a use of the invention may comprise obtaining of a measured level of expression of said miR-124 into an isolated biological sample and comparing said measured level of expression to a control reference value.
- An observation of a modulation of said measured level relative to said control reference value may be indicative of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.
- the measured level expression of miR-124 may be at least a two-fold, preferably at least a four-fold, preferably at least a six-fold, preferably at least an eight-fold, and more preferably at least a ten-fold decrease relative to said control reference value.
- the miR-124 biomarker may be used to monitor or manage a patient suffering from a viral infection, and in particular a retroviral infection, and more particularly an HIV infection or AIDS (Acquired Immune Deficiency Syndrome).
- a viral infection and in particular a retroviral infection, and more particularly an HIV infection or AIDS (Acquired Immune Deficiency Syndrome).
- HIV infection or AIDS Acquired Immune Deficiency Syndrome
- the uses and methods of the invention may be for assessing a responsiveness of a patient to a treatment with said quinoline derivatives of formula
- the uses and methods of the invention may be for assessing an effectiveness of a treatment with said quinoline derivative of formula (I).
- a use or a method according to the invention may be implemented for optimizing the dosing regimen of a patient.
- Patients may respond differently to a given quinoline derivative of formula (I), depending on such factors as age, health, genetic background, presence of other complications, disease progression, and the co-administration of other drugs.
- It may be useful to utilize the miR-124 biomarker to assess and optimize the dosage regimen, such as the dose amount and/or the dose schedule, of a quinoline derivative in a patient.
- miR-124-based biomarker can also be used to track and adjust individual patient treatment effectiveness over time. The biomarker can be used to gather information needed to make adjustments in a patient's treatment, increasing or decreasing the dose of an agent as needed.
- a patient receiving a quinoline derivative can be tested using the miR-124 -based biomarker to see if the dosage is becoming effective, or if a more aggressive treatment plan needs to be put into place.
- the amount of administered drug, the timing of administration, the administration frequency, the duration of the administration may be then adjusted depending on the miR-124 biomarker measurement.
- the miR-124 biomarker may also be used to track patient compliance during individual treatment regimes, or during clinical trials. This can be followed at set intervals to ensure that the patients included in the trial are taking the drugs as instructed. Furthermore, a patient receiving a quinoline derivative can be tested using the miR-124 biomarker to determine whether the patient complies with the dosing regimen of the treatment plan. An increased expression level of the biomarker compared to that of an untreated control sample is indicative of compliance with the protocol.
- a biomarker of the invention may be implemented to assess and follow the efficacy of quinoline derivatives of formula (I). Accordingly, a presence or level of expression of miR-124 may be measured into an isolated biological sample obtained from a patient previously treated with a quinoline derivative of formula (I). Then, the measured presence or level expression of miR-124 into an isolated biological sample may be compared to a control reference value.
- the measure is indicative of an activity of said quinoline derivatives of formula (I).
- the measure when an increase of the measured level relative to the control reference value is observed, then the measure may be indicative of a responsiveness of a patient to a treatment with said quinoline derivatives of formula (I).
- the measure when an increase of the measured level relative to the control reference value is observed, then the measure may be indicative of an effectiveness of a treatment with said quinoline derivatives of formula (I).
- the measure when an increase of the measured level of expression relative to the control reference value is observed, then the measure may be indicative a therapeutic efficacy of said quinoline derivatives of formula (I) as a therapeutic agent for preventing and/or treating a viral infection.
- the measured level expression of miR-124 may be at least a two-fold, preferably at least a four-fold, preferably at least a six-fold, preferably at least an eight-fold, and more preferably at least a ten-fold increase relative to said control reference value.
- a patient when monitoring a viral infection or assessing an efficacy of a viral infection treatment, in particular with a quinoline derivative of formula (I), a patient may be tested with a method or a use of the invention at a time interval selected from the group consisting of hourly, twice a day, daily, twice a week, weekly, twice a month, monthly, twice a year, yearly, and every other year. The then collected sample can be tested immediately, or can be stored for later testing.
- use and methods according to the invention may, in particular, allow for the screening, identification or evaluation of potential active agents as a drug candidate.
- use and methods according to the invention are particularly advantageous for the screening, identification or evaluation of potential active agents, such as a drug candidate or a vaccine presumed effective towards a viral infection.
- a miR-124 biomarker may be implemented to screen a drug candidate or a vaccine candidate presumed effective for preventing and/or treating a viral infection.
- a presence or level of expression of miR- 124 may be measured into an isolated biological sample or isolated cell previously contacted with the drug or vaccine to be screened. Then, the obtained measure may be compared to a control reference value.
- the measure may be indicative of said candidate to have a biological effect and in particular to be efficient for altering the physiological activity of a cell.
- a drug candidate or vaccine candidate may be characterized as being efficient in preventing and/or treating a viral infection, and in particular a retroviral infection, and more particularly an HIV infection.
- miR-124 from a sample is "increased” or "up-regulated” after treatment with a drug candidate or vaccine , as compared to a non- treated control reference value, this increase can be, for example, of about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100%, 200%, 300%, 500%, 1,000%, 5,000% or more of the comparative control reference value (i.e., without the treatment by the quinoline derivative).
- the measured level expression of miR-124 may be at least a two-fold, preferably at least a four-fold, preferably at least a six-fold, preferably at least an eight-fold, and more preferably at least a ten-fold increase relative to said control reference value.
- a biological sample suitable for the invention may be a biological fluid, such as a blood, a plasma, or a serum, a saliva, an interstitial fluid, or an urine sample; a cell sample, such as a cell culture, a cell line, or a PBMC sample, a tissue biopsy, such as an oral tissue, a gastrointestinal tissue, a skin, an oral mucosa sample, or a plurality of samples from a clinical trial.
- the sample can be a crude sample, or can be purified to various degrees prior to storage, processing, or measurement.
- the step of collecting biological samples for the uses and methods of the invention is performed before carrying out the invention and is not a step of a use or a method in accordance with the invention.
- Samples for miRNA assessment can be taken during any desired intervals. For example, samples can be taken hourly, twice per day, daily, weekly, monthly, every other month, yearly, or the like. The sample can be tested immediately, or can be stored for later testing.
- Control reference value to be used for comparing the measured level of expression of miR-124 in a tested biological sample is obtained from a control sample.
- a control reference value may be obtained from an isolated biological sample obtained on an individual or group of individuals known to not suffer from such condition.
- a control reference value may be obtained from an isolated biological sample obtained from an individual or group of individuals known to not suffer from such condition, and not receiving the treatment the efficacy of which is to be determined or monitored.
- a control reference value may be obtained from an isolated biological sample obtained from a patient suffering from a viral infection and receiving a treatment the efficacy of which being to be determined or monitored, the isolated biological sample being taken from the patient before administration of the treatment. Numerous methods are available to the skilled man to measure a presence or level of expression of the miR-124 biomarker.
- nucleic acid assays or arrays can be used to assess the presence and/or expression level of miR-124 in a sample.
- the sequence of the miR-124 may be used to prepare a corresponding nucleotide acting as complementary probe or primer to be used in different nucleic acid assays for detecting the expression or presence of the miR-124 biomarker in the sample, such as, but not limited to, Northern blots and PCR-based methods (e.g., Real-Time Reverse Transcription-PCR or qRT- PCR). Methods such as qRT-PCR may be used to accurately quantitate the amount of the miRNA in a sample.
- a method for the detection and quantification of nucleic acids may be a hybridation-based method.
- Said hybridation-based methods may include PCR and quantitative-PCR (qRT-PCR or q-PCR) techniques or reverse transcriptase / polymerase based techniques.
- said method may comprise, or be further combined, with a sequencing step.
- Those methods may comprise (i) a step of extraction of cellular mRNAs, (ii) a step of reverse transcription of mRNA to DNA using a reverse transcriptase and (iii) a step of DNA amplification from DNA obtained on the previous step.
- the following nucleic acids are amplified : (a) DNA obtained after a reverse transcription step of the target mRNA and (b) a DNA or a plurality of DNAs obtained after reverse transcription of mRNAs which are constitutively and constantly expressed by cells ( « housekeeping genes »), such as RNAs coded by genes MRP L 19, PUM1 and GADPH.
- the amplified DNA can be quantified, after separation by electrophoresis, and measure of DNA bands. Results related to the target mRNA(s) are expressed as relative units in comparison to mRNAs coded by « housekeeping » genes.
- the step of separation of amplified DNAs is achieved after agarose gel electrophoresis, and then coloration of DNA bands with ethidium bromide, before quantification of DNA contained in those migration bands with densitometry.
- a micro-channel device in which amplified DNA is separated by capillar electrophoresis, before quantification of the emitted signal using a laser beam.
- Such a device may be a LabChip® device, for instance from the « GX » series, commercialized by the company Caliper LifeSciences (Hopkinton, MA, USA).
- Quantitative results obtained by qRT-PCR can sometimes be more informative than qualitative data, and can simplify assay standardization and quality management.
- qRT-PCR-based assays can be useful to measure miRNA levels during cell-based assays.
- the qRT-PCR method may be also useful in monitoring patient therapy.
- Commercially available qRT-PCR based methods ⁇ e.g., TaqmanR ArrayTM)
- an oligonucleotide array for testing for quinoline derivative or drug candidate activity in a biological sample can be prepared or purchased.
- An array typically contains a solid support and at least one oligonucleotide contacting the support, where the oligonucleotide corresponds to at least a portion of the miR-124 biomarker.
- the portion of the miR-124 biomarker comprises at least 5, 10, 15, 20 or more bases.
- the presence or expression of miR-124 may be assayed in combination with others miRNA also used as biomarkers.
- an array can be used to assess the expression or presence of multiple miRNAs in a sample, including miRNA-124.
- the method comprises the following steps: a) contacting the sample with an array comprising a probe set under conditions sufficient for specific binding to occur; and b) examining the array to detect the presence of any detectable label, thereby evaluating the amount of the respective target miRNAs in the sample.
- the use of an expression array allows obtaining a miRNA expression profile for a given sample.
- the polynucleotide arrays typically are fabricated on planar supports either by depositing previously obtained polynucleotides onto the support in a site specific fashion or by site specific in situ synthesis of the polynucleotides upon the support.
- Arrays to detect miRNA expression can be fabricated by depositing (e.g., by contact- or jet-based methods or photolithography) either precursor units (such as nucleotide or amino acid monomers) or pre-synthesized capture agent. After depositing the polynucleotide capture agents onto the support, the support is typically processed (e.g., washed and blocked for example) and stored prior to use.
- an array to detect miRNA expression has at least two, three, four, or five different subject probes.
- a subject array may include a probe set having at least 10, at least 20, at least 50, at least 100, at least 200, at least 500, or at least 1,000 or more probes that can detect a corresponding number of miRNAs.
- the subject arrays may include probes for detecting at least a portion or all of the identified miRNAs of an organism, or may include orthologous probes from multiple organisms.
- a nucleic acid array may be contacted with a sample or labeled sample containing miRNA analytes under conditions that promote specific binding of the miRNA in the sample to one or more of the capture agents present on the array to exhibit an observed binding pattern.
- This binding pattern can be detected upon interrogating the array.
- the target miRNAs in the sample can be labeled with a suitable label (such as a fluorescent compound), and the label then can be accurately observed (such as by observing the fluorescence pattern) on the array after exposure of the array to the sample.
- the observed binding pattern can be indicative of the presence and/or concentration of one or more miRNA components of the sample.
- the labeling of miRNAs may be carried using methods well known in the art, such as using DNA ligase, terminal transferase, or by labeling the RNA backbone, etc.
- the miRNAs may be labeled with fluorescent label.
- Exemplary fluorescent dyes include but are not limited to xanthene dyes, fluorescein dyes, rhodamine dyes, fluorescein isothiocyanate (FITC), 6 carboxyfluorescein (FAM), 6 carboxy-2 1 ,4 1 ,7',4,7- hexachlorofluorescein (HEX), 6 carboxy 4', 5' dichloro 2', 7' dimethoxyfluorescein (JOE or J), ⁇ , ⁇ , ⁇ ', ⁇ ' tetramethyl 6 carboxyrhodamine (TAMRA or T), 6 carboxy X rhodamine (ROX or R), 5 carboxyrhodamine 6G (R6G5 or G5), 6 carboxyrh
- Cy3, Cy5 and Cy7 dyes include Alexa dyes, e.g. Alexa-fluor-555; coumarin, Diethylaminocoumarin, umbelliferone; benzimide dyes, e.g. Hoechst 33258; phenanthridine dyes, e.g.
- an oligonucleotide array for assessing immunomodulatory activity can be prepared or purchased, for example from Affymetrix.
- the array may contain a solid support and a plurality of oligonucleotides contacting the support.
- the oligonucleotides may be present in specific, addressable locations on the solid support; each corresponding to at least a portion of miRNA sequences which may be differentially expressed upon treatment of a quinoline derivative or a drug candidate in a cell or a patient.
- the miRNA sequences comprise at least one miR-124 sequence.
- Hybridization can be carried out under suitable hybridization conditions, which may vary in stringency as desired. Typical conditions are sufficient to produce probe/target complexes on an array surface between complementary binding members, i.e., between surface-bound subject probes and complementary miRNAs in a sample.
- stringent hybridization conditions may be employed.
- Hybridization is typically performed under stringent hybridization conditions. Standard hybridization techniques which are well-known in the art (e.g. under conditions sufficient to provide for specific binding of target miRNAs in the sample to the probes on the array) are used to hybridize a sample to a nucleic acid array.
- the miRNA expression profiling experiments may be conducted using the Affymetrix Genechip miRNA Array 2.0 and following the protocols described in the instruction manual.
- said hybridization can be performed using the GeneChip® Hybridization, Wash, and Stain Kit (Affymetrix Ref. #900720).
- said hybridization is performed by following the protocols of the manufacturer.
- the array-surface bound polynucleotides are typically washed to remove unbound nucleic acids. Washing may be performed using any convenient washing protocol, where the washing conditions are typically stringent, as described above. For instance, a washing step may be performed using washing buffers sold by the company Affymetrix (Ref. #900721 and #900722).
- the hybridization of the target miRNAs to the probes is then detected using standard techniques of reading the array. Reading the resultant hybridized array may be accomplished, for example, by illuminating the array and reading the location and intensity of resulting fluorescence at each feature of the array to detect miRNA/probe binding complexes.
- MicroRNAs are small, single-stranded non-coding RNAs that can act in the cytoplasm of a cell to cause a decrease in the expression of their cognate target messenger RNAs or translation of the mRNA's protein product. Mature miRNAs are typically about 19-23 nucleotides in length. This ability of miRNAs to inhibit the production of their target proteins results in the regulation of many types of cellular activities, such as cell-fate determination, apoptosis, differentiation, and oncogenesis.
- the miR-124 microRNA precursor is a small non-coding RNA molecule.
- the mature -21 nucleotide microRNAs are processed from hairpin precursor sequences by the Dicer enzyme.
- the mature sequences are SEQ ID NO: 4, UAAGGCACGCGGUGAAUGCC for miR-124-3' and SEQ ID NO: 5, CGUGUUCACAGCGGACCUUGAU for miR-124-5'.
- miRNA-124 is preferentially expressed in brain, and could contribute to neurogenesis by downregulating SCPl expression. Expression of miR124 in mouse neuronal cells induces a switch from general to neuron-specific alternative splicing by directly targeting the mRNA of PTBP1. miR-124 increases the abundance of neuron-specific PTBP2 and Gabbrl mRNAs by preventing PTBP1 -dependent exon skipping that leads to nonsense-mediated decay of these mRNAs.
- EAE Experimental autoimmune encephalomyelitis
- CNS central nervous system
- miR-124 is as highly expressed in microglia and neurons. Expression of miR-124 is reduced in activated microglia during an EAE episode and in activated microglia in culture. Transfection of miR-124 deactivates bone marrow-derived macrophages, and intravenous administration of miR-124 inhibits development of lesions and reduced CNS inflammation in 3 mouse models of EAE. It has been found that miR-124 promotes microglia quiescence by deactivating macrophages via the CEBPA-PU.1 pathway.
- An isolated nucleic acid probe suitable for measuring a presence or level expression of miR-124 is a nucleic acid probe able to specifically hybridize to a miR-124, such as a precursor or a mature miR-124.
- a nucleic acid probe may comprise from 18 to 30 nucleotides, in particular from 20 to 27, preferably from 20 to 25, preferably from 20, 22, or 25, and more preferably about 25 nucleotides.
- nucleic acid probes may be prepared according to any known methods in the art.
- the man skilled in the art may easily calculate an optimal hybridization temperature based on a set of probes, on a given target sequence, and with particular conditions of hybridization.
- the optimal hybridization temperature of said probes is between
- buffers useful for hybridizing a nucleic acid probe of the invention to a biomarker of the invention one may mention, as an hybridization buffer, a buffer comprising lOOmM MES, 1M [Na+], 20mM EDTA, 0.01% Tween-20, as a non-stringent washing buffer a buffer comprising 6X SSPE, 0.01% Tween-20, and as a stringent washing buffer a buffer comprising lOOmM MES, 0.1M [Na+], 0.01% Tween-20.
- a nucleic acid probe suitable for measuring a presence or level expression of miR- 124 may, for instance, be a nucleic acid probe consisting in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 87.
- a nucleic acid probe suitable for measuring a presence or level expression of the miR- 124-1 precursor may, for instance, be a nucleic acid probe consisting in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 34, SEQ ID NO 86 and SEQ ID NO 87.
- a nucleic acid probe suitable for measuring a presence or level expression of the miR- 124-2 precursor may, for instance, be a nucleic acid probe consisting in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 35 to SEQ ID NO: 65, SEQ ID NO 86 and SEQ ID NO 87.
- a nucleic acid probe suitable for measuring a presence or level expression of the miR- 124-3 precursor may, for instance, be a nucleic acid probe consisting in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 66 to SEQ ID NO: 85, SEQ ID NO 86 and SEQ ID NO 87.
- a nucleic acid probe suitable for measuring a presence or level expression of a mature miR- 124 may, for instance, be a nucleic acid probe consisting in a nucleic acid sequence selected from the group consisting of SEQ ID NO 86 and SEQ ID NO 87.
- the quinoline derivatives useful for the invention may be quinoline derivatives efficient for treating a viral infection, such as the ones described in WO 2010/143169.
- quinoline derivatives useful for the invention are quinoline derivatives which may be represented by the following general formula I):
- R and R" are preferably a hydrogen atom.
- R independently, represents a fluorine or a chlorine atom or a group chosen among methyl or ethyl group, a -NH 2 group, a methoxy or ethoxy group, and a (C 1 -C 3 ) fluoroalkoxy group.
- n is preferably 1.
- quinoline derivatives useful for the invention are quinoline derivatives which may be represented by a quinoline derivative of formula (II): wherein:
- R independently, represents a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 ) alkyl group; a -CN group; a hydroxyl group; a -COORi group; a (Ci-C 3 )fluoroalkyl group; a -NO 2 group; a -NR 1 R 2 group with Ri and R 2 being a hydrogen atom or a (Ci-C 3 )alkyl group; and a (C 1 -C 4 ) alkoxy group,
- R' is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C4) alkyl group and a (C 1 -C 4 ) alkoxy group,
- R" is a hydrogen atom or a (C 1 -C 4 ) alkyl group
- a quinoline derivative suitable for the invention may be of formula (II), in which R, independently, represents a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 ) alkyl group, a (C 1 -C 3 ) fluoroalkyl group, a hydroxyl group, a - CN group, a-COOH group and a (Ci-C 3 )alkoxy group.
- R independently, represents a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 ) alkyl group, a (C 1 -C 3 ) fluoroalkyl group, a hydroxyl group, a - CN group, a-COOH group and a (Ci-C 3 )alkoxy group.
- a quinoline derivative suitable for the invention may be of formula (II), in which R, independently, represents a hydrogen atom, a halogen atom, a -CN group, a (C 1 -C 3 ) alkyl group, a (C 1 -C 3 ) fluoroalkyl group, and a hydroxyl group.
- a quinoline derivative suitable for the invention may be of formula (II), in which R, independently, represents a (C 1 -C 3 ) fluoroalkyl group.
- n is preferably 1.
- a quinoline derivative may be represented by the following formula:
- a quinoline derivative useful for the invention may be selected from a group consisting of:
- Salts of a quinoline derivative of the invention and more particularly of a compound having the general formula (I) or (II) and of inorganic acid suitable for the invention may be obtained with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid.
- Salts of a quinoline derivative of the invention and more particularly of a compound having the general formula (I) or (II) and of organic acid suitable for the invention may be obtained with carboxylic acids and sulfonic acids such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic acid, succinic acid, malonic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid or p-toluenesulfonic acid.
- carboxylic acids and sulfonic acids such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic acid, succinic acid, malonic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid or p-toluenesulfonic acid.
- the treatment can be oral or parenteral administration of a quinoline derivative. Suitable modes of administration and regimen are described in WO 2010/143169.
- a quinoline derivative can be administered by oral, parenteral, intravenous, transdermal, intramuscular, rectal, sublingual, mucosal, nasal, or other means.
- a quinoline derivative can be administered in a form of pharmaceutical composition and/or unit dosage form.
- RNAs were extracted according to manufacturer's instructions. Extracted RNAs quality and amount were controlled using Agilent Bioanalyzer 2100 and Nanodrop spectrophotometry ND-1000. Mean RIN value was 8.84 (from 7.2 to 9.7). A total RNA amount of 90 ng per sample was labeled using FlashTagTM Biotin HSR RNA Labeling Kit (901911) and hybridized overnight to the Affymetrix Genechip miRNA Array 2.0. (901753) The arrays were washed and stained using standard Affymetrix protocol and scanned using the Affymetrix Scanner. Quality controls were performed using Expression Console metrics from Affymetrix (version 1.2).
- miR-124 is validated as being a relevant biomarker to monitor the efficacy of quinoline derivatives according to the invention as anti-viral drugs in AIDS patient, and in particular the 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine.
- Example 2 assesses the variation of miR-124 expression in the absence of HIV-l. The screening method was tested to evaluate a set of quinoline derivatives and known antiretroviral drugs such as Maraviroc, Efavirenz, Darunavir and azidothymidine (AZT).
- known antiretroviral drugs such as Maraviroc, Efavirenz, Darunavir and azidothymidine (AZT).
- PBMCs Peripheral blood mononuclear cells
- the cells are then resuspended at 37°C to a density of l,5xl0 6 cells/mL in RPMI Glutamax medium (Life Technologies Ref 61870-010) supplemented with 10% fetal calf serum (FCS) (Thermo Fischer Ref SV30160.03) and without activation. Cells are incubated for 48 hours at 37°C under 5% C0 2 .
- each well comprising 3.10 6 cell/4 ml RPMI supplemented with 10% fetal calf serum and 40 U/mL IL-2 (Peprotech Ref 200-02) are added screened molecules. 100% DMSO (0,8 ⁇ is added to the well and tested as a negative control.
- 6x10 6 cells are recovered and centrifugated at 1200 rpm for 5 minutes.
- the cell pellet is lysed in 300 ⁇ L of ML lysis buffer from the Macherey Nagel Nucleospin® miRNA extraction kit (Macherey Nagel Ref 740971), and further stored at -20°C.
- the reverse transcription step is followed for 12 ⁇ ⁇ of miRNA using the miScript RT
- RT reverse transcription
- the quantitative PCR step is achieved using the QIAGEN ® miScnpt SYBR ® Green
- results show good agreement between Relative and Absolute quantification for all molecules.
- DMSO control samples have a fold-change of 1, meaning no variation in miR-124a expression.
- All the tested quinoline derivatives show a modulation of miR-124 corresponding to a ten-fold increase of the expression of miR-124.
- other antiretroviral drugs do not induce significant modulation of the expression of miR-124.
- this Example shows that the miR-124 is a suitable biomarker for screening a drug candidate or vaccine candidate presumed effective in preventing and/or treating a viral infection. It is also particularly useful for assessing the activity of a quinoline derivative of the invention.
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2015008703A MX363726B (en) | 2013-01-17 | 2014-01-17 | miRNA-124 AS A BIOMARKER. |
PL14703438T PL2946022T3 (en) | 2013-01-17 | 2014-01-17 | Mirna-124 as a biomarker |
US14/761,674 US11441181B2 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 as a biomarker |
ES14703438T ES2716104T3 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 as a biomarker |
JP2015553212A JP6607568B2 (en) | 2013-01-17 | 2014-01-17 | MiRNA-124 as a biomarker |
AU2014206553A AU2014206553B2 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 as a biomarker |
EP14703438.3A EP2946022B1 (en) | 2013-01-17 | 2014-01-17 | Mirna-124 as a biomarker |
KR1020157022175A KR102412581B1 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 as a biomarker |
CN201480011638.3A CN105612261B (en) | 2013-01-17 | 2014-01-17 | MiRNA-124 as biomarker |
BR112015016977-5A BR112015016977B1 (en) | 2013-01-17 | 2014-01-17 | IN VITRO OR EX VIVO USE OF MIRNA AND IN VITRO OR EX VIVO METHOD TO EVALUATE A VIRAL INFECTION |
CA2897563A CA2897563C (en) | 2013-01-17 | 2014-01-17 | Mirna-124 as a biomarker |
RU2015133373A RU2687366C2 (en) | 2013-01-17 | 2014-01-17 | Microrna-124 as biomarker |
KR1020227009514A KR102575595B1 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 as a biomarker |
DK14703438.3T DK2946022T3 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 AS A BIOMARKER |
ZA2015/04984A ZA201504984B (en) | 2013-01-17 | 2015-07-10 | Mirna-124 as a biomarker |
HK16106678.8A HK1218766A1 (en) | 2013-01-17 | 2016-06-10 | Mirna-124 as a biomarker mirna-124 |
HRP20190436TT HRP20190436T1 (en) | 2013-01-17 | 2019-03-04 | miRNA-124 AS A BIOMARKER |
AU2019283919A AU2019283919A1 (en) | 2013-01-17 | 2019-12-19 | miRNA-124 as a biomarker |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305053.4A EP2757161A1 (en) | 2013-01-17 | 2013-01-17 | miRNA-124 as a biomarker of viral infection |
EP13305053.4 | 2013-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014111892A1 true WO2014111892A1 (en) | 2014-07-24 |
Family
ID=47628077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/058359 WO2014111892A1 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 AS A BIOMARKER |
Country Status (19)
Country | Link |
---|---|
US (1) | US11441181B2 (en) |
EP (2) | EP2757161A1 (en) |
JP (1) | JP6607568B2 (en) |
KR (2) | KR102412581B1 (en) |
CN (1) | CN105612261B (en) |
AU (2) | AU2014206553B2 (en) |
BR (1) | BR112015016977B1 (en) |
CA (1) | CA2897563C (en) |
DK (1) | DK2946022T3 (en) |
ES (1) | ES2716104T3 (en) |
HK (1) | HK1218766A1 (en) |
HR (1) | HRP20190436T1 (en) |
MX (1) | MX363726B (en) |
PL (1) | PL2946022T3 (en) |
PT (1) | PT2946022T (en) |
RU (1) | RU2687366C2 (en) |
TR (1) | TR201903401T4 (en) |
WO (1) | WO2014111892A1 (en) |
ZA (1) | ZA201504984B (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016009065A3 (en) * | 2014-07-17 | 2016-03-24 | Abivax | Quinoline derivatives for the treatment of inflammatory diseases |
EP3669874A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
EP3881844A1 (en) | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
WO2021186053A1 (en) | 2020-03-20 | 2021-09-23 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
EP3884946A1 (en) | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
US11441181B2 (en) | 2013-01-17 | 2022-09-13 | Abivax | miRNA-124 as a biomarker |
WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2440545T3 (en) | 2009-06-12 | 2019-07-22 | Abivax | Compounds useful for treating cancer |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
CA2916623C (en) * | 2013-07-05 | 2021-09-14 | Abivax | Bicyclic compounds useful for treating diseases caused by retroviruses |
EP3058940A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
EP3921446A1 (en) * | 2019-02-05 | 2021-12-15 | Universidade de Santiago de Compostela | In vitro method for the diagnosis of viral infections |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007042899A2 (en) * | 2005-10-10 | 2007-04-19 | Council Of Scientific And Industrial Research | Human microrna targets in hiv genome and a method of identification thereof |
WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
WO2009132273A2 (en) * | 2008-04-25 | 2009-10-29 | Merck & Co., Inc. | Microrna biomarkers of tissue injury |
WO2010143169A2 (en) | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
BE486034A (en) | 1947-11-28 | |||
DE958647C (en) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Process for the preparation of 7-amino-2-oxy-4-methyl-quinolines |
FR2387229A1 (en) | 1977-04-13 | 1978-11-10 | Anvar | DIPYRIDO (4,3-B) (3,4-F) INDOLES, PROCESS FOR OBTAINING, THERAPEUTIC APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2436786A1 (en) | 1978-09-21 | 1980-04-18 | Anvar | NOVEL PYRIDO (4,3-B) CARBAZOLES (ELLIPTICINS) DERIVATIVES, SUBSTITUTED IN POSITION 1 BY A POLYAMINE CHAIN, THEIR OBTAINMENT AND THEIR APPLICATION AS MEDICAMENTS |
US4738710A (en) | 1979-11-19 | 1988-04-19 | Ici Australia Limited | Herbicidal alkane carboxylic acid derivatives |
FR2627493B1 (en) | 1988-02-23 | 1991-10-31 | Sanofi Sa | PROCESS FOR THE PREPARATION OF ISOQUINOLEIN DERIVATIVES |
FR2645861A1 (en) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | USE OF DIPYRIDO (4,3-B) (3,4-F) INDOLES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF AIDS |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
DE60008509T2 (en) | 1999-04-05 | 2004-12-16 | City Of Hope, Duarte | New inhibitors of advanced glycosylation end products (AGEs) |
UA75055C2 (en) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon |
DE10013318A1 (en) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Quinoxaline derivatives are used as photo-stable UV filters in cosmetic or pharmaceutical sunscreens for the hair or skin |
CN100378075C (en) | 2001-01-22 | 2008-04-02 | 记忆药物公司 | Aniline derivative using as phosphodiesterase 4 inhibitor |
US6498254B1 (en) | 2001-10-29 | 2002-12-24 | Uniroyal Chemical Company, Inc. | Antiretroviral compounds and compositions |
CA2486376A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
JP2006504656A (en) | 2002-07-19 | 2006-02-09 | メモリー・ファーマシューティカルズ・コーポレイション | Phosphodiesterase 4 inhibitors comprising N-substituted anilines and diphenylamine analogues |
WO2006081444A2 (en) | 2005-01-28 | 2006-08-03 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
FR2849474B3 (en) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | INSTALLATION FOR TRANSFORMING THE KINETIC ENERGY OF A FLUID INTO ELECTRIC ENERGY |
WO2004078731A1 (en) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
MXPA05009722A (en) | 2003-03-10 | 2006-03-09 | Schering Corp | Heterocyclic kinase inhibitors: methods of use and synthesis. |
FR2859474B1 (en) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT USEFUL IN THE TREATMENT OF GENETIC DISEASES RESULTING FROM THE ALTERATION OF SPLICE PROCESSES |
FR2859475A1 (en) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Use of ellipticin, or its aza-derivatives, in treatment of genetic disorders caused by alteration of RNA splicing, e.g. parkinsonism, neuropathy and cancers |
CA2542329A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
AU2004293019B2 (en) | 2003-11-19 | 2010-10-28 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US8633219B2 (en) * | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
CA2585490A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
CN101213260A (en) | 2005-06-29 | 2008-07-02 | 株式会社Adeka | Resin additive composition and resin composition thereof |
RU2350650C2 (en) * | 2006-04-17 | 2009-03-27 | Общество с ограниченной ответственностью "Биосинтез" (ООО "Биосинтез") | RECOMBINANT PLASMIDE DNA pVar15-HIV-LTR, CARRYING CLONED FRAGMENT GENOME HIV OF 1 TYPE FROM CONSERVATIVE SITE OF 5-LTR SEQUENCE, RECOMBINANT PLASMIDE DNA pBluKSM-HIV-LTR mod CARRYING CLONED MODIFIED FRAGMENT OF SAME SITE GENOME HIV OF 1 TYPE, TEST SET FOR QUANTITATIVE EXPRESS IDENTIFICATION OF GENOME HIV-1 OF ANY TYPE IN ASSAY AND METHOD WITH ITS USE |
WO2007147217A1 (en) | 2006-06-22 | 2007-12-27 | Prana Biotechnology Limited | Method of treatment of glioma brain tumour |
FR2903312B1 (en) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT |
US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
AU2008206045A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
FR2912745A1 (en) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | NEW INDOLE-DERIVED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2008115870A2 (en) | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
WO2008143440A1 (en) | 2007-05-17 | 2008-11-27 | Lg Chem, Ltd. | New anthracene derivatives and organic electronic device using the same |
WO2008153692A2 (en) * | 2007-05-22 | 2008-12-18 | The Brigham And Women's Hospital, Inc. | Microrna expression profiling of cerebrospinal fluid |
UY31272A1 (en) | 2007-08-10 | 2009-01-30 | Almirall Lab | NEW DERIVATIVES OF AZABIFENILAMINOBENZOIC ACID |
KR20100053626A (en) | 2007-08-15 | 2010-05-20 | 메모리 파마슈티칼스 코포레이션 | 3' substituted compounds having 5-ht6 receptor affinity |
WO2009029617A1 (en) | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
KR100974562B1 (en) | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
FR2926297B1 (en) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | INHIBITORY CHEMICAL MOLECULES IN THE SPLICE MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICE ANOMALIES. |
JP2009174368A (en) | 2008-01-23 | 2009-08-06 | Toyota Motor Corp | Exhaust emission device of internal combustion engine |
US20160041153A1 (en) * | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
JP2012520891A (en) * | 2009-03-19 | 2012-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method for producing sulfonylquinoline |
WO2010129451A1 (en) | 2009-05-05 | 2010-11-11 | Boehringer Ingelheim International Gmbh | Process for preparing bromo-substituted quinolines |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
MX2019008390A (en) | 2009-06-12 | 2019-09-09 | Abivax | Compounds useful for treating cancer. |
US8962583B2 (en) | 2009-06-25 | 2015-02-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory diseases using miR-124 |
WO2011057003A2 (en) | 2009-11-04 | 2011-05-12 | Samuil Umansky | Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
WO2012118988A1 (en) * | 2011-03-01 | 2012-09-07 | The Scripps Research Institute | Direct reprogramming of human fibroblasts to functional neurons under defined conditions |
AU2012309226B2 (en) * | 2011-09-15 | 2017-12-14 | Self-Screen B.V. | Methylation analysis on self-samples as triage tool for HPV-positive women |
US20150272959A1 (en) | 2012-10-04 | 2015-10-01 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
ES2899926T3 (en) | 2016-03-18 | 2022-03-15 | Prosynergia S A R L | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
-
2013
- 2013-01-17 EP EP13305053.4A patent/EP2757161A1/en not_active Withdrawn
-
2014
- 2014-01-17 ES ES14703438T patent/ES2716104T3/en active Active
- 2014-01-17 MX MX2015008703A patent/MX363726B/en active IP Right Grant
- 2014-01-17 KR KR1020157022175A patent/KR102412581B1/en active IP Right Grant
- 2014-01-17 AU AU2014206553A patent/AU2014206553B2/en active Active
- 2014-01-17 CA CA2897563A patent/CA2897563C/en active Active
- 2014-01-17 TR TR2019/03401T patent/TR201903401T4/en unknown
- 2014-01-17 EP EP14703438.3A patent/EP2946022B1/en active Active
- 2014-01-17 US US14/761,674 patent/US11441181B2/en active Active
- 2014-01-17 RU RU2015133373A patent/RU2687366C2/en active
- 2014-01-17 CN CN201480011638.3A patent/CN105612261B/en active Active
- 2014-01-17 PT PT14703438T patent/PT2946022T/en unknown
- 2014-01-17 BR BR112015016977-5A patent/BR112015016977B1/en active IP Right Grant
- 2014-01-17 KR KR1020227009514A patent/KR102575595B1/en active IP Right Grant
- 2014-01-17 JP JP2015553212A patent/JP6607568B2/en active Active
- 2014-01-17 DK DK14703438.3T patent/DK2946022T3/en active
- 2014-01-17 WO PCT/IB2014/058359 patent/WO2014111892A1/en active Application Filing
- 2014-01-17 PL PL14703438T patent/PL2946022T3/en unknown
-
2015
- 2015-07-10 ZA ZA2015/04984A patent/ZA201504984B/en unknown
-
2016
- 2016-06-10 HK HK16106678.8A patent/HK1218766A1/en unknown
-
2019
- 2019-03-04 HR HRP20190436TT patent/HRP20190436T1/en unknown
- 2019-12-19 AU AU2019283919A patent/AU2019283919A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007042899A2 (en) * | 2005-10-10 | 2007-04-19 | Council Of Scientific And Industrial Research | Human microrna targets in hiv genome and a method of identification thereof |
WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
WO2009132273A2 (en) * | 2008-04-25 | 2009-10-29 | Merck & Co., Inc. | Microrna biomarkers of tissue injury |
WO2010143169A2 (en) | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
Non-Patent Citations (21)
Title |
---|
ALTUVIA ET AL., NUCLEIC ACIDS RESEARCH, vol. 33, no. 8, 2005, pages 2697 - 2706 |
BARTEL ET AL., CELL, vol. 136, no. 2, 2009, pages 215 - 233 |
BASKERVILLE ET AL., RNA, vol. 11, no. 3, 2005, pages 241 - 247 |
BING ZENG ET AL: "Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3", FEBS LETTERS, vol. 586, no. 19, 1 September 2012 (2012-09-01), pages 3271 - 3278, XP055064924, ISSN: 0014-5793, DOI: 10.1016/j.febslet.2012.06.049 * |
BUSTIN, JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 25, 2000, pages 169 - 193 |
DE WONG ET AL., BIO TECHNIQUES, vol. 39, no. 1, 2005, pages 75 - 85 |
GUO ET AL., PLOS ONE, vol. 4, no. 11, 2009, pages E7944 |
HOUZET ET AL., BIOCHIM BIOPHYS ACTA, vol. 1809, no. 11-12, November 2011 (2011-11-01), pages 686 - 693 |
KENNETH W WITWER ET AL: "Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients", RETROVIROLOGY, vol. 9, no. 1, 1 January 2012 (2012-01-01), pages 5, XP055034302, ISSN: 1742-4690, DOI: 10.1186/1742-4690-9-5 * |
KIM ET AL., EMBO JOURNAL, vol. 26, no. 3, 2007, pages 775 - 783 |
KLINCK ET AL., CANCER RESEARCH, vol. 68, 2008, pages 657 - 663 |
LAI ET AL., NATURE GENETICS, vol. 30, no. 4, 2002, pages 363 - 364 |
LEE, EMBO J., vol. 21, 2002, pages 4663 - 4670 |
LINDOW, DNA CELL BIOL., vol. 26, no. 5, 2007, pages 339 - 351 |
LIU, CELL RESEARCH, vol. 18, no. 10, 2008, pages 985 - 996 |
MARCO PACIFICI ET AL: "Cerebrospinal fluid miRNA profile in HIV-encephalitis", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 228, no. 5, 28 January 2013 (2013-01-28), pages 1070 - 1075, XP055064929, ISSN: 0021-9541, DOI: 10.1002/jcp.24254 * |
NAIR, TRENDS IN MICROBIOL., vol. 14, 2006, pages 169 - 175 |
NOLAN ET AL., NAT PROTOC, vol. 1, no. 3, 2006, pages 1559 - 1582 |
OZSOLAK ET AL., GENES AND DEVELOPMENT, vol. 22, no. 22, 2008, pages 3172 - 3183 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOUR, N. Y. |
WANG ET AL., PROC NATL ACAD SCI USA, vol. 86, 1989, pages 917 - 921 |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11441181B2 (en) | 2013-01-17 | 2022-09-13 | Abivax | miRNA-124 as a biomarker |
EP3998070A1 (en) * | 2014-07-17 | 2022-05-18 | Abivax | Mir-124 as a biomarker for the treatment of inflammatory diseases |
US10435370B2 (en) | 2014-07-17 | 2019-10-08 | Abivax | Quinoline derivatives for the treatment of inflammatory diseases |
US11649211B2 (en) | 2014-07-17 | 2023-05-16 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
US11649210B2 (en) | 2014-07-17 | 2023-05-16 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
AU2021201960B2 (en) * | 2014-07-17 | 2023-02-23 | Abivax | Quinoline derivatives for the treatment of inflammatory diseases |
WO2016009065A3 (en) * | 2014-07-17 | 2016-03-24 | Abivax | Quinoline derivatives for the treatment of inflammatory diseases |
US10981874B2 (en) | 2014-07-17 | 2021-04-20 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
WO2020127843A1 (en) | 2018-12-20 | 2020-06-25 | Abivax | Quinoline derivatives for use in the treatment of inflammation diseases |
WO2020127839A1 (en) | 2018-12-20 | 2020-06-25 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
EP3669874A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
WO2021186053A1 (en) | 2020-03-20 | 2021-09-23 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
EP3881844A1 (en) | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
EP3884946A1 (en) | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023135207A1 (en) | 2022-01-13 | 2023-07-20 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
WO2023139233A1 (en) | 2022-01-24 | 2023-07-27 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
Also Published As
Publication number | Publication date |
---|---|
CN105612261A (en) | 2016-05-25 |
BR112015016977B1 (en) | 2022-11-08 |
US11441181B2 (en) | 2022-09-13 |
KR20220038551A (en) | 2022-03-28 |
AU2014206553B2 (en) | 2020-01-16 |
RU2015133373A (en) | 2017-02-21 |
HRP20190436T1 (en) | 2019-06-14 |
HK1218766A1 (en) | 2017-03-10 |
EP2946022B1 (en) | 2019-01-09 |
DK2946022T3 (en) | 2019-04-08 |
JP6607568B2 (en) | 2019-11-20 |
CA2897563C (en) | 2021-08-31 |
ES2716104T3 (en) | 2019-06-10 |
BR112015016977A2 (en) | 2017-08-15 |
EP2946022A1 (en) | 2015-11-25 |
MX363726B (en) | 2019-04-01 |
KR102575595B1 (en) | 2023-09-06 |
US20150361491A1 (en) | 2015-12-17 |
PL2946022T3 (en) | 2019-06-28 |
KR102412581B1 (en) | 2022-06-23 |
AU2019283919A1 (en) | 2020-01-16 |
CN105612261B (en) | 2019-06-18 |
TR201903401T4 (en) | 2019-04-22 |
RU2687366C2 (en) | 2019-05-13 |
CA2897563A1 (en) | 2014-07-24 |
EP2757161A1 (en) | 2014-07-23 |
ZA201504984B (en) | 2016-09-28 |
MX2015008703A (en) | 2016-04-15 |
JP2016505268A (en) | 2016-02-25 |
PT2946022T (en) | 2019-03-21 |
KR20150109407A (en) | 2015-10-01 |
AU2014206553A1 (en) | 2015-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2897563C (en) | Mirna-124 as a biomarker | |
JP6862475B2 (en) | A method of estimating the prognosis of patients with malignant diseases and predicting their responsiveness to immunotherapy | |
US11649211B2 (en) | Use of quinoline derivatives for the treatment of inflammatory diseases | |
JP5965481B2 (en) | MicroRNA profiling for diagnosis of cutaneous T-cell lymphoma (CTCL) | |
WO2008064519A1 (en) | Methods and compositions for diagnosis of esophageal cancer and prognosis and improvement of patient survival | |
WO2015175660A1 (en) | Mirna expression signature in the classification of thyroid tumors | |
EP2808387B1 (en) | Oligonucleotide for hiv detection, hiv detection kit, and hiv detection method | |
TWI698640B (en) | Methods for detecting or assessing the risk of developing lupus nephritis and application thereof | |
JP5757908B2 (en) | Polymorph detection probe, polymorph detection method, drug efficacy evaluation method, disease prediction method, and polymorph detection reagent kit | |
JP7218887B2 (en) | Specimens for cervical cancer screening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14703438 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/008703 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014703438 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2897563 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015553212 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14761674 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014206553 Country of ref document: AU Date of ref document: 20140117 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015016977 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015133373 Country of ref document: RU Kind code of ref document: A Ref document number: 20157022175 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015016977 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150715 |